Get the Stockscreener App
2.42
3.97%
-0.10
After Hours:
2.46
0.04
+1.65%
Yd Bio Ltd stock is traded at $2.42, with a volume of 14,456.
It is down -3.97% in the last 24 hours and down -52.17% over the past month.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
See More
Previous Close:
$2.52
Open:
$2.45
24h Volume:
14,456
Relative Volume:
0.63
Market Cap:
$171.41M
Revenue:
-
Net Income/Loss:
$-2.97M
P/E Ratio:
-2.4494
EPS:
-0.988
Net Cash Flow:
$-1.18M
1W Performance:
-25.54%
1M Performance:
-52.17%
6M Performance:
-78.65%
1Y Performance:
+0.00%
1-Day Range:
$2.3783
$2.655
1-Week Range:
$2.3783
$3.5499
52-Week Range:
$2.3783
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
2.42 | 178.49M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Yd Bio Ltd Stock (YDES) Latest News
BRZHR Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
YD Bio Ord Shs (YDES) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
YD Bio Ord Shs (YDES) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
YD Bio Ord Shs (YDES) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
YD Bio Ord Shs (YDES) Institutional Confidence - TradingKey
YD Bio Ord Shs (YDES) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
YD Bio Ord Shs (YDES) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
YD Bio Ord Shs (YDES) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
YD Bio Ord Shs (YDES) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
YD Bio Ord Shs (YDES) Valuation: PE, PB & Fair Value Analysis - TradingKey
Morning Market Movers: SLBT, SCLX, TDIC, CRE See Big Swings - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
[EFFECT] YD Bio Ltd SEC Filing - Stock Titan
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - Yahoo Finance
YD Bio Stock Is Falling Again: The SEC Filing Behind the Slide - Bez Kabli
iGan Partners Invests in Adenocyte Ltd to Advance the Early Detection of Pancreatic Cancer - Yahoo Finance
YD Bio (NASDAQ: YDES) prospectus lists 58.6M resale shares, 11.4M exercisable - Stock Titan
Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX) - Yahoo Finance
Registrar Corp and U.S. Commercial Service Strengthen Partnership to Support Australian Companies Expanding into the U.S. - Yahoo Finance
Yourgene Health Launches Insight DPYD Assay - Yahoo Finance
Affiliated (MGRE) Steady at $$24.02 — Awaiting Next Catalyst 2026-05-13Rip Sell Trade - The Legal Advocate
YD Bio Limited Ordinary Shares Stock Forecast Summary - Meyka
Autoliv posts upbeat Q1 results, joins United Airlines, Royal Caribbean Cruises and other big stocks moving higher on Friday - MSN
YD Bio Limited Reports Full Year 2025 Financial Results - ChartMill
YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations - Quiver Quantitative
YD Bio 2025 Loss/Shr 12c >YDES - Moomoo
After a $13.9M equity raise, YD Bio enters 2026 with $6M cash - Stock Titan
Going concern warning tops YD Bio (NASDAQ: YDES) 20-F risk disclosures - Stock Titan
ClearNote Health to Present Industry-Leading Early Detection Data for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 - Yahoo Finance
New LowStock ScreenerSnapshot - Finviz
Immuneering Corp (IMRX) Stock Price, Quote, News & History - Benzinga
CMMB (Chemomab Therapeutics Ltd. American Depositary Share) posts narrower Q4 2025 loss than estimates, while shares dip modestly.Community Trade Ideas - Xã Thanh Hà
What is happening with Elbit Systems (ESLT) stock today (Smart Money Active) 2026-04-20High Interest Stocks - Cổng thông tin điện tử tỉnh Lào Cai
[Form 3/A] YD Bio Ltd Amended Initial Statement of Beneficial Ownership - Stock Titan
Shao Ta Lu Net Worth (2026) - GuruFocus
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Friday - Sahm
Man Edmund Hen Net Worth (2026) - GuruFocus
Bo Xiang Zhang Net Worth (2026) - GuruFocus
Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Movi - Benzinga
GFL ENVIRONMENTAL INC. (GFL) - MSN
How does macroeconomics affect YD Bio (YDES) Stock | Price at $5.97, Down 4.57%Portfolio Management - newser.com
Is YD Bio (YDESW) Stock slowing down | Price at $0.58, Down 10.08%Market Hype Signals - Newser
Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness - Yahoo Finance
YDES Technical Analysis & Stock Price Forecast - Intellectia AI
YDES SEC FilingsYD Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
CRVL Stock Analysis: CorVel Corp. notches 1.6 pct daily gain near 54 key support - The Legal Advocate
YD Bio (YDES) director receives $60,000 RSU grant and 2,081 shares - Stock Titan
Director at YD Bio (YDES) receives $60K RSU equity award - Stock Titan
YD Bio (NASDAQ: YDES) director Lu Shao-Ta files initial Form 3 - Stock Titan
Director Chang Kochi logs initial insider status at YD Bio Ltd (YDES) - Stock Titan
YD Bio launches telehealth platform for cancer detection By Investing.com - Investing.com South Africa
Yd Bio Ltd Stock (YDES) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):